PURPOSE: This study explores the prevalence of self-reported taste and smell changes (TSCs) during chemotherapy and relationships between TSCs and demographic and clinical factors. MATERIALS AND METHODS: Consecutive patients who had received chemotherapy for > or =6 weeks at 11 outpatient chemotherapy units completed a questionnaire developed for this survey. RESULTS: Seventy-five percent of the 518 participants reported TSCs, with TSCs more prevalent among women and younger patients. After adjustment for age and sex, we found that patients reporting TSCs more often reported: previous smell changes, less responsibility for cooking, concurrent medication, higher educational levels, and being on sick leave. Participants reporting oral problems, nausea, appetite loss, and depressed mood more frequently reported TSCs. Diagnosis and type of chemotherapy regimen did not predict TSCs. CONCLUSION: TSCs were found to be common during cancer chemotherapy and were related to sociodemographic rather than clinical factors. TSCs were also found to be closely related to many other side effects of chemotherapy.
PURPOSE: This study explores the prevalence of self-reported taste and smell changes (TSCs) during chemotherapy and relationships between TSCs and demographic and clinical factors. MATERIALS AND METHODS: Consecutive patients who had received chemotherapy for > or =6 weeks at 11 outpatient chemotherapy units completed a questionnaire developed for this survey. RESULTS: Seventy-five percent of the 518 participants reported TSCs, with TSCs more prevalent among women and younger patients. After adjustment for age and sex, we found that patients reporting TSCs more often reported: previous smell changes, less responsibility for cooking, concurrent medication, higher educational levels, and being on sick leave. Participants reporting oral problems, nausea, appetite loss, and depressed mood more frequently reported TSCs. Diagnosis and type of chemotherapy regimen did not predict TSCs. CONCLUSION: TSCs were found to be common during cancer chemotherapy and were related to sociodemographic rather than clinical factors. TSCs were also found to be closely related to many other side effects of chemotherapy.
Authors: R S Wickham; M Rehwaldt; C Kefer; S Shott; K Abbas; E Glynn-Tucker; C Potter; C Blendowski Journal: Oncol Nurs Forum Date: 1999-05 Impact factor: 2.172
Authors: M Alvarez-Camacho; S Gonella; S Ghosh; C Kubrak; R A Scrimger; K P Chu; W V Wismer Journal: Qual Life Res Date: 2015-11-20 Impact factor: 4.147
Authors: Yeon-Hee Kim; Gun Min Kim; Sungtaek Son; Mina Song; Sangun Park; Hyun Cheol Chung; Seung-Min Lee Journal: Support Care Cancer Date: 2019-06-22 Impact factor: 3.603
Authors: Sofia Pugnaloni; Arianna Vignini; Francesca Borroni; Jacopo Sabbatinelli; Sonila Alia; Mara Fabri; Marina Taus; Laura Mazzanti; Rossana Berardi Journal: Support Care Cancer Date: 2019-06-15 Impact factor: 3.603
Authors: Alissa Nolden; Paule V Joseph; Kord M Kober; Bruce A Cooper; Steven M Paul; Marilyn J Hammer; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-07-23 Impact factor: 3.612
Authors: Peter Hevezi; Bryan D Moyer; Min Lu; Na Gao; Evan White; Fernando Echeverri; Dalia Kalabat; Hortensia Soto; Bianca Laita; Cherry Li; Shaoyang Anthony Yeh; Mark Zoller; Albert Zlotnik Journal: PLoS One Date: 2009-07-28 Impact factor: 3.240